NCT06084104

DZD9008 PK Study in Hepatic Impairment Subjects

A Phase 1, Single-Dose, Non-Randomized, Open Label Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of DZD9008

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Dizal Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function

Conditions

• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	DZD9008	A single oral dose of 200mg DZD9008
DRUG	DZD9008	A single oral dose of 200mg DZD9008

Timeline

• Start date: 2023-10-17
• Primary completion: 2024-06-12
• Completion: 2024-10-23
• First posted: 2023-10-16
• Last updated: 2024-12-18

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study